Significant EU funding for international AICCELERATE consortium proposing a scalable AI tool for smart hospital

The AICCELERATE consortium consists of specialists in the fields of IT, machine learning, robotics, neurology, paediatrics and surgery from Finland, Italy, Spain, Turkey, Netherlands, Germany and Belgium.
Healthcare systems lack flexible AI solutions that allow hospitals to improve efficiency and the quality of patient care. Current solutions provide limited scalability and are confined to isolated applications. Scalable models that address data sharing, integration, privacy, and ethics are needed to ensure better adoption of AI in healthcare. Patient empowerment and evidence-based trust towards AI is a key part of the project. Evaluation activities will also focus on cost-benefit analysis of the AI-solutions.
AICCELERATE will develop partners’ existing digital solutions further to enable the development of a Smart Hospital Care Pathway (SHCP) Engine. This engine serves as a toolset for AI models and robotics to improve quality of care and health outcomes. It will also enable lean management and effective decision-making.
These tools are tested in three pilots that will provide feedback for improving the SHCP Engine: (i) patient flow management for ER and surgical units, (ii) digital care pathway for Parkinson’s disease, and (iii) paediatric service delivery.
The pilots are carried out by 5 hospital partners: Helsinki University Hospital and Oulu University Hospital from Finland, Ospedale Pediatrico Bambino Gesù from Italy, Barcelona Children's Hospital from Spain, and University Hospital Università degli Studi di Padova from Italy.
In addition to these above mentioned hospitals The AICCELERATE consortium is formed by Erasmus Univ. Rotterdam from Netherlands, RTO Fundació Eurecat from Spain, a Spanish non-profit TICBioMed, 6 SMEs aiming to advance the digitalization of the European healthcare services: Chino from Italy, Symptoma from Austria, Nuromedia from Germany, SRDC from Turkey, Evondos from Finland, NeuroPath from Belgium, and 2 large enterprises NEC Laboratories Europe from Germany and Innofactor from Finland. The preparation of the proposal was supported by Spinverse from Finland.
Keywords
Contacts
More information:
Development Manager Tuuli Pajunen
tuuli.pajunen@hus.fi, +358 40 182 5028
Research and Innovation Manager Suzan Ikävalko,
suzan.ikavalko@hus.fi, +358 50 583 4292
Images
About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Valviras beslut om tillgången till icke brådskande specialiserad sjukvård är mycket hårt9.10.2025 12:10:08 EEST | Pressmeddelande
Den budgetram som HUS-sammanslutningen har fått gör det inte möjligt att avhjälpa vårdköerna. Målet under 2024–2025 har varit att i bästa fall stoppa en ökning av vårdköerna. Tillgången till vård har ändå förbättrats betydligt.
Valviran päätös kiireettömään erikoissairaanhoitoon pääsystä erittäin ankara9.10.2025 12:10:08 EEST | Tiedote
HUS-yhtymälle annettu talousarvioraami ei mahdollista hoitojonojen purkamista. Vuosina 2024−2025 tavoitteena on ollut parhaimmillaan hoitojonojen kasvun pysäyttäminen. Hoitoonpääsyä on silti onnistuttu parantamaan merkittävästi.
Unga vuxna som genomgått en transplantation i barndomen behöver flera läkemedel mot kroniska sjukdomar9.10.2025 08:13:26 EEST | Pressmeddelande
I en nyligen färdigställd studie framgick det att personer som genomgått en transplantation som barn har högre benägenhet för långvariga sjukdomar än den övriga befolkningen och behöver flera läkemedel mot kroniska sjukdomar än andra personer i samma ålder.
Lapsuudessa elinsiirron saaneet nuoret aikuiset tarvitsevat enemmän lääkkeitä kroonisiin sairauksiin9.10.2025 08:13:26 EEST | Tiedote
Vasta valmistuneessa tutkimuksessa selvisi, että lapsena elinsiirron saaneet ovat muuta väestöä alttiimpia pitkäaikaisille sairauksille, ja tarvitsevat enemmän lääkkeitä kroonisiin sairauksiin kuin muut samanikäiset.
Den palliativa vården för barn utvecklas aktivt8.10.2025 08:39:53 EEST | Pressmeddelande
Palliativ vård för barn och unga är övergripande vård, där hela familjen beaktas. Vi HUS utvecklas den palliativa vården för barn aktivt bland annat inom det europeiska projektet PALLIAKID. Projektets syfte är att ännu bättre än tidigare identifiera patienter som har nytta av palliativ vård.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom